Lincoln Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Lincoln Pharmaceuticals Ltd reported a 3.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 28.5%.
- Its expenses for the quarter were up by 0.4% QoQ and 28.1% YoY.
- The net profit decreased 10.4% QoQ and increased 48.1% YoY.
- The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 9.3 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 149.51 | 155.52 | 116.36 | -3.9% | 28.5% |
Total Expenses | 127.30 | 126.84 | 99.38 | 0.4% | 28.1% |
Profit Before Tax | 22.22 | 28.68 | 16.98 | -22.5% | 30.9% |
Tax | 3.62 | 7.91 | 4.42 | -54.2% | -18.1% |
Profit After Tax | 18.60 | 20.77 | 12.56 | -10.4% | 48.1% |
Earnings Per Share | 9.30 | 10.40 | 6.30 | -10.6% | 47.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lincoln Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, focusing primarily on the production and distribution of a wide range of pharmaceutical products. The company's portfolio includes various formulations in the therapeutic areas of anti-infectives, cardiovascular, gastrointestinal, and more, aimed at meeting the healthcare needs of diverse populations. Notably, Lincoln Pharmaceuticals has been active in expanding its product offerings and market reach, although specific recent developments were not provided in the data. The company operates in a highly competitive sector characterized by rapid technological advancements and stringent regulatory standards.
Revenue
In the fourth quarter of FY25, Lincoln Pharmaceuticals Ltd reported a total income of ₹149.51 crores. This reflects a quarter-over-quarter (QoQ) decline of 3.9% compared to ₹155.52 crores in Q3FY25. Conversely, a year-over-year (YoY) comparison shows a substantial increase of 28.5% from ₹116.36 crores in Q4FY24. The revenue growth on a yearly basis suggests robust performance in sales or potentially expanded market operations compared to the previous year. However, the QoQ decline indicates a potential seasonal or operational variation in revenue generation.
Profitability
Profitability metrics highlight a nuanced picture for Lincoln Pharmaceuticals Ltd in Q4FY25. The company achieved a profit before tax (PBT) of ₹22.22 crores, showing a significant QoQ decrease of 22.5% from ₹28.68 crores in Q3FY25. Despite this, the YoY growth stands at 30.9% from ₹16.98 crores in the previous year. The profit after tax (PAT) for Q4FY25 was ₹18.60 crores, representing a QoQ decline of 10.4% from ₹20.77 crores in Q3FY25 but a substantial YoY increase of 48.1% from ₹12.56 crores in Q4FY24. Earnings per share (EPS) also followed a similar pattern with a QoQ decline of 10.6% yet a YoY rise of 47.6%.
Operating Metrics
Total expenses for Lincoln Pharmaceuticals Ltd in Q4FY25 were ₹127.30 crores, marking a slight QoQ increase of 0.4% from ₹126.84 crores in Q3FY25, and a YoY increase of 28.1% from ₹99.38 crores in Q4FY24. The tax expense for the quarter was ₹3.62 crores, significantly lower by 54.2% QoQ from ₹7.91 crores in Q3FY25, and also showing a YoY decrease of 18.1% from ₹4.42 crores in Q4FY24. This decrease in tax expenditure contributes to the overall profitability margins for the company. While specific financial ratios like P/E ratio, debt-to-equity ratio, or current ratio were not provided, the available metrics indicate significant fluctuations in operating costs and tax obligations, which are crucial for assessing the operating efficiency of the company.